Last reviewed · How we verify

Oral Anticoagulant, Direct-Acting

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

Oral Anticoagulant, Direct-Acting is a Direct-acting oral anticoagulant (DOAC) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment. Also known as: HMG-CoA reductase inhibitors, platelet aggregation inhibitors from the P2Y12 receptor antagonist group.

Direct-acting oral anticoagulants inhibit specific clotting factors (typically Factor Xa or thrombin) to prevent blood clot formation.

Direct-acting oral anticoagulants inhibit specific clotting factors (typically Factor Xa or thrombin) to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment.

At a glance

Generic nameOral Anticoagulant, Direct-Acting
Also known asHMG-CoA reductase inhibitors, platelet aggregation inhibitors from the P2Y12 receptor antagonist group
SponsorAssistance Publique - Hôpitaux de Paris
Drug classDirect-acting oral anticoagulant (DOAC)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Direct-acting oral anticoagulants (DOACs) work by selectively inhibiting key enzymes in the coagulation cascade without requiring monitoring or cofactors like vitamin K. They provide rapid onset of anticoagulant effect and predictable pharmacokinetics, making them suitable for oral administration in conditions requiring thromboembolism prevention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral Anticoagulant, Direct-Acting

What is Oral Anticoagulant, Direct-Acting?

Oral Anticoagulant, Direct-Acting is a Direct-acting oral anticoagulant (DOAC) drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment.

How does Oral Anticoagulant, Direct-Acting work?

Direct-acting oral anticoagulants inhibit specific clotting factors (typically Factor Xa or thrombin) to prevent blood clot formation.

What is Oral Anticoagulant, Direct-Acting used for?

Oral Anticoagulant, Direct-Acting is indicated for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment.

Who makes Oral Anticoagulant, Direct-Acting?

Oral Anticoagulant, Direct-Acting is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Oral Anticoagulant, Direct-Acting also known as anything else?

Oral Anticoagulant, Direct-Acting is also known as HMG-CoA reductase inhibitors, platelet aggregation inhibitors from the P2Y12 receptor antagonist group.

What drug class is Oral Anticoagulant, Direct-Acting in?

Oral Anticoagulant, Direct-Acting belongs to the Direct-acting oral anticoagulant (DOAC) class. See all Direct-acting oral anticoagulant (DOAC) drugs at /class/direct-acting-oral-anticoagulant-doac.

What development phase is Oral Anticoagulant, Direct-Acting in?

Oral Anticoagulant, Direct-Acting is in Phase 3.

What are the side effects of Oral Anticoagulant, Direct-Acting?

Common side effects of Oral Anticoagulant, Direct-Acting include Bleeding (major and minor), Gastrointestinal bleeding, Dyspepsia.

Related